First and only once-daily triple therapy in a single inhaler for adult patients with COPD or ASTHMA

TRELEGY delivers an ICS, a LABA, and a LAMA in an easy-to-use1,2 ELLIPTA inhaler

TRELEGY dosing considerations for 2 indications: COPD & ASTHMA

Inhalers solo
Inhaler Solo

Instruct ALL patients to:

  • Take TRELEGY as 1 inhalation, once daily, at the same time every day
  • Use TRELEGY only once every 24 hours
  • After inhalation, rinse the mouth with water without swallowing to reduce the risk of oropharyngeal candidiasis
  • Treat acute symptoms with an inhaled SABA such as albuterol

No dosage adjustment is required for geriatric patients, patients with renal impairment, or patients with moderate hepatic impairment.

For patients with COPD:

TRELEGY 100/62.5/25 mcg is the only strength indicated for treatment of COPD.

For patients with ASTHMA:

Either strength—100/62.5/25 mcg or 200/62.5/25 mcg—can be the starting dose.

When choosing the starting dose, consider:

  • Patients’ disease severity and their previous asthma therapy, including the ICS dosage
  • Patients’ current control of asthma symptoms and risk of future exacerbation

Maximum recommended dosage is 1 inhalation of TRELEGY 200/62.5/25 mcg once daily.

For patients who do not respond adequately to TRELEGY 200/62.5/25 mcg once daily, re-evaluate and consider other therapeutic regimens and additional therapeutic options.

For more details:

See Dosage and Administration in the full Prescribing Information.

 
 
 

Simplified delivery of triple therapy: 3 medications. 1 daily inhalation. 1 easy-to-use1,2 ELLIPTA inhaler.

Features of TRELEGY ELLIPTA
Preloaded

Preloaded

Each inhaler contains 30 doses.

Single-step Dose Activation

Single-step Dose Activation

Dose is ready when cover is opened fully; counter shows how many doses remain.

Breath Actuated

Breath Actuated

Requires no hand-breath coordination.

Preloaded

Preloaded

Each inhaler contains 30 doses.

Single-step Dose Activation

Single-step Dose Activation

Dose is ready when cover is opened fully; counter shows how many doses remain.

Breath Actuated

Breath Actuated

Requires no hand-breath coordination.

TRELEGY contains 2 foil blister strips with 30 daily doses of ICS, LABA, and LAMA

Inhaler inside

One strip contains:

  • Fluticasone furoate (100 mcg OR 200 mcg per blister), the ICS in TRELEGY

One strip contains a blend of:

  • Umeclidinium (62.5 mcg per blister), the LAMA in TRELEGY
  • Vilanterol (25 mcg per blister), the LABA in TRELEGY

Together the blister strips also contain inactive ingredients:

  • Lactose monohydrate and magnesium stearate

Could once-daily triple therapy in a single inhaler make a difference for your patients?

According to the GOLD 2020 Report:

  • Use of multiple inhalers for COPD is one factor that may lead to poor inhaler technique3

According to the GINA 2020 Report:

  • Use of multiple different inhaler types for ASTHMA may lead to confusion for patients and may reduce effective use of inhalers4

TRELEGY does not replace a rescue inhaler. Acute symptoms should be treated with an inhaled SABA.

Could once-daily triple therapy in a single inhaler make a difference for your patients?

According to the GOLD 2020 Report:

  • Use of multiple inhalers for COPD is one factor that may lead to poor inhaler technique3

According to the GINA 2020 Report:

  • Use of multiple different inhaler types for ASTHMA may lead to confusion for patients and may reduce effective use of inhalers4

TRELEGY does not replace a rescue inhaler. Acute symptoms should be treated with an inhaled SABA.

ELLIPTA inhaler rated “easy-to-use” by >90% of patients with COPD or ASTHMA in studies that assessed correct use1,2

Results of easy-to-use studies1,2

At the conclusion of two 4-week clinical studies, 1 in ASTHMA and 1 in COPD:

  • 96% (239/250) of patients with ASTHMA demonstrated correct use and rated the ELLIPTA inhaler easy to use1
  • 93% (248/266) of patients with COPD demonstrated correct use and rated the ELLIPTA inhaler easy to use2

Inhalers did not contain active treatment.

  • Description of COPD and ASTHMA easy-to-use studies

    Study descriptions1,2

    Inhalers did not contain active treatment.

    Design: One study was conducted in patients with COPD (N=266) and one study was conducted in patients with ASTHMA (N=250).

    Both studies were 28-day, open-label, placebo studies designed to assess ease of use of the ELLIPTA inhaler among adult patients who used the inhaler correctly on Day 28. Correct use was evaluated using instructions derived from the prescribing information for products delivered in the ELLIPTA inhaler. At enrollment, patients were allowed up to 3 attempts to demonstrate correct use (with training between attempts 1 and 2, and 2 and 3, if necessary), and all patients were able to demonstrate correct use. On Day 28, patients were evaluated for correct use in a single attempt without additional instruction.

    In the COPD study, 97% of patients demonstrated correct use. In the ASTHMA study, 98% of patients demonstrated correct use. “Easy to use” was defined as a rating of very easy or easy on a 4 point scale (very easy, easy, difficult, very difficult).

Easy to use

 

 
 
 

TRELEGY MOA: triple action

TRELEGY delivers 3 complementary mechanisms of action (MOA). The MOA described for the individual components apply to TRELEGY. These drugs represent 3 different classes of medications (an ICS, a LABA, and a LAMA), each having different effects on clinical and physiological indices.

moa
  1. ICS REDUCES inflammation
  2. LABA ACTIVATES bronchodilation
  3. LAMA INHIBITS bronchoconstriction

 

Review Instructions for Use in Patient Information.

Download now

 

Show your patients how to use the inhaler

Watch video

 

See helpful resources for your practice and your patients.

Explore resources

Explore the clinical data for once-daily TRELEGY in COPD.

Learn more